Daptomycin: a comparison of two intravenous formulations

Abstract

Daptomycin is a cyclic lipopeptide antibacterial agent with potent bactericidal activity against a broad range of Gram-positive organisms. In 2003, daptomycin for injection received approval from the US Food and Drug Administration (FDA) for the treatment of patients with complicated skin and skin structure infections (cSSSIs); in 2006, it was approved for the treatment of patients with Staphylococcus aureus bacteremia, including those with right-sided infective endocarditis caused by methicillin-susceptible and methicillin-resistant isolates. In 2016, the FDA approved a new formulation of daptomycin for injection (daptomycin RF) for the same indications. The efficacy and safety of daptomycin for injection have been established in pivotal clinical trials, and the findings of nonclinical studies indicate that both formulations of daptomycin for injection are equivalent. Herein we refer to the new daptomycin formulation as daptomycin RF to distinguish it from the original formulation. Daptomycin RF provides clinicians and clinical pharmacists with a product that offers improved stability and more rapid, in-vial reconstitution with either sterile or bacteriostatic water for injection, while maintaining the same antibacterial coverage. Here we discuss the rationale for and the potential value of daptomycin RF, and briefly review the similarities and differences between the original formulation of daptomycin and daptomycin RF.

Streptomyces as a Prominent Resource of Future Anti-MRSA Drugs

“…By definition, MRSA are resistant to penicillin-like antibiotics, and they have now been noted to be developing resistance to other existing classes of antibiotics (Kaur and Chate, 2015 ). There is a constant hunt for new antibiotics but in the last few decades, only a limited number have been added to the clinician's arsenal; among them are linezolid in 2000 (Lee and Caffrey, 2017 ), daptomycin (a lipopeptide) in 2003 (Frankenfeld et al, 2018 ) and ceftaroline in 2010 (Long et al, 2014 ). Presently, vancomycin remains the most important first-line therapy for severe MRSA infection.…”

“…Based on historical evidence, Streptomyces seem to be a viable target in the hunt for new drugs as they represent the source of 75% of clinically useful antibiotics presently available (Janardhan et al, 2014 ). One of the newer antibiotics currently in use, daptomycin, represents the latest contribution of Streptomyces in the fight against pathogenic microbes—it was discovered in the 1980s and approved by the US Food and Drug Regulatory Administration (US FDA) for clinical use in 2003 (Frankenfeld et al, 2018 ). To date, Streptomyces -derived daptomycin remains the only naturally produced antibiotic of a novel class introduced since 2003 and it is currently considered a first-line drug for treatment of MRSA bacteremia (Choo and Chambers, 2016 ).…”

Statistical Medium Optimization for the Production of Anti-Methicillin-Resistant Staphylococcus aureus Metabolites from a Coal-Mining-Soil-Derived Streptomyces rochei CMB47

“…The tabulated t value [40][41][42] for a 5% level of significance and five degrees of freedom (f = 6 − 1 = 5) is t 0.05 (5) The test of regression significance has been carried out via Fisher's variance ratio test, known as the F-test. The F-ratio is given by the following form:…”

“…The worldwide emergence of MRSA strains poses a serious public health problem because they are responsible for a wide variety of infections [3]. Moreover, there are limited therapeutic options still available [4][5][6] due to the small number of antibiotics that have been added to the clinician's arsenal in the last few decades.…”

Acquisition of Daptomycin Resistance by Enterococcus faecium Confers Collateral Sensitivity to Glycopeptides

“…In 2003, daptomycin (DAP)—a cyclic lipopeptide antibacterial agent—was approved by the Food and Drug Administration for the treatment of complex skin and soft tissue infections, due to its rage of activity against methicillin-resistant S. aureus (MRSA) and vancomycin-resistant Enterococci (VRE) ( Frankenfeld et al, 2018 ). However, with its extensive use in clinical settings, the number of treatment failures reported with DAP has been increasing ( Jones et al, 2008 ; Lellek et al, 2015 ; Ji et al, 2020 ).…”